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Abstract
Background: MicroRNAs (miRNAs) negatively regulate the gene expression and act as tumor suppressors or oncogenes in
oncogenesis. The association between single nucleotide polymorphism (SNP) in miR-196a2 rs11614913 and the
susceptibility of digestive system cancers was inconsistent in previous studies.
Methodology/Principal Findings: An updated meta-analysis based on 15 independent case-control studies consisting of
4999 cancer patients and 7606 controls was performed to address this association. It was found that miR-196a2
polymorphism significantly elevated the risks of digestive system cancers (CT vs. TT, OR=1.25, 95% CI=1.07–1.45; CC vs. TT,
OR=1.38, 95% CI=1.13–1.67; CC/CT vs. TT, OR=1.29, 95% CI=1.10–1.50; CC vs. CT/TT, OR=1.14, 95% CI=1.01–1.30; C vs. T,
OR=1.15, 95% CI=1.05–1.26). We also found that variant in miR-196a2 increased the susceptibility of colorectal cancer
(CRC) (CT vs. TT, OR=1.23, 95% CI=1.04–1.44; CC vs. TT, OR=1.32, 95% CI=1.08–1.61; CC/CT vs. TT, OR=1.25, 95%
CI=1.07–1.46; C vs. T, OR=1.15, 95% CI=1.05–1.28), while the association in recessive model (CC vs. CT/TT, OR=1.16, 95%
CI=0.98–1.38) showed a marginal significance. Additionally, significant association between miR-196a2 polymorphism and
increased risk of hepatocellular cancer (HCC) was detected. By stratifying tumors on the basis of site of origin, source of
controls, ethnicity and allele frequency in controls, elevated cancer risks were observed.
Conclusion/Significance: Our findings suggest the significant association between miR-196a2 polymorphism and increased
susceptibility of digestive system cancers, especially of CRC, HCC and Asians. Besides, C allele may contribute to increased
digestive cancer risks.
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Introduction
MicroRNAs (miRNAs) are endogenous, small non-coding and
have a length of 18–25 nucleotides RNAs. miRNAs can interact
with messenger RNAs (mRNAs) by binding to 39 un-translated
regions (UTRs) and lead to the degradation or translational
repression of mRNAs. Studies revealed that miRNAs played key
roles in various biological processes including cell growth
regulation, differentiation, apoptosis and tumorigenesis [1,2,3].
miRNAs regulate approximately 30% of human genes and exhibit
a remarkable contribution to carcinogenesis [2,4]. Aberrant
modulation of specific miRNAs was considered to be a crucial
event of diverse diseases including cancers [5] although the
detailed process of miRNAs expression and mutation are still
ambiguous. Moreover, some studies detected that miRNAs
participated in the etiology, progression and prognosis of cancers,
such as non-small cell lung cancer [6] and hepatocellular
carcinoma [7]. Several possible mechanisms, including genetic
and epigenetic alternations, have been proposed. SNPs in
miRNAs are marked as novel genetic variations which may
modify the cancer susceptibilities [8]. Genetic variant in miR-
196a2 had been demonstrated to be associated with some cancer
risks, but different studies showed conflicting associations. Meta-
analysis on breast cancer, lung cancer and other cancers revealed
that rs11614913 was a functional SNP and had potential ability to
modify the cancer risks [9,10,11,12,13].
As we know, the above-referenced meta-analysis included
gastric cancer (GC), HCC and other digestive cancers for the
SNP in miR-196a2. However, by the limitation of inadequate
publications, they did not calculate pooled ORs of digestive system
cancers comprehensively. To improve the efficiency of meta-
analysis on digestive cancers and reduce the potential between-
study heterogeneity which might derive from various cancers in
diverse systems, we focused on digestive system cancers only and
added more recent publications on CRC [14,15,16] and HCC
[17] in this study. We also contacted the authors to request for
genotype frequencies about oral cavity squamous cancer (OSCC)
and pharynx squamous cancer (PSCC) [18,19] which were not
shown in published articles. In addition, an unpublished case-
control study on CRC which was performed by Mingwu Zhang
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University School of Medicine was collected. Overall, 9 datasets
from 7 studies (including2875 cases withdigestive cancers and 5556
controls) which had not been studied in previous meta-analysis were
additionally included in our study. And we performed this meta-
analysis focusing on the following issues: (a) What is the association
between miR-196a2 polymorphism and the susceptibility of
digestive system cancers, especially of colorectal cancer? (b) Would
changes in tumor sites, demographic characteristics and other
factors transform this association significantly?
Materials and Methods
Identification of eligible studies
A systematic search in PubMed was conducted using a
retrieving query formulation ‘‘(microrna 196a2 OR rs11614913)
polymorphisms cancer’’ (last search updated on 20 Aug, 2011). We
also searched references in published articles and reviews on this
topic in PubMed. Eligible studies were selected according to the
following explicit inclusion criteria: (a) Study was designed using
the methodology of a case-control study. (b) The association
between miR-196a2 polymorphism and digestive system cancer
risks was explored. (c) There was sufficient data for the
computation of odds ratios and corresponding 95% confidence
intervals (ORs, 95% CIs). (d) Cases with carcinomas were
diagnosed by histopathology. Moreover, we also contacted some
researchers to request unpublished study outcomes and detailed
datasets for pooled calculation (Figure 1).
Data extraction
Two investigators (Guo and Jin) screened titles, abstracts and
full texts independently using a standardized screening guide. Data
extraction was carried out independently after the concealment of
authors, journals, supporting organizations and funds to avoid
investigators’ bias. After data abstraction, discrepancies and
differences were resolved by consensus and discussion.
Characteristics of enrolled studies were assigned to the
structured form (Table 1), including first author’s name,
publication time, study country origin, ethnicity, cancer type,
source of controls, genotyping method, matched criteria between
cases and controls, sample size, C allele frequency in controls
(Table S1), genotype frequency distribution and quality scores.
Methodological quality assessment
Three reviewers (Guo, Jin and Zhang) independently evaluated
the quality of selected studies by scoring according to a set of
predetermined criteria (Table S2) which was extracted and
modified from previous studies [20,21,22]. Quality scores ranged
from 0 to 10 and the studies with higher scores presented better
quality. Disagreements were resolved by discussion.
Statistical analysis
Crude ORs and corresponding 95%CIs were calculated to
investigate the association strength between miR-196a2 polymor-
phism and the susceptibility of digestive system cancers. Pooled
ORs were obtained from combination of single studies by
heterozygote comparison (CT vs. TT), homozygote comparison
(CC vs. TT), dominant and recessive models (CC/CT vs. TT, CC
vs. CT/TT), allelic comparison (C vs. T) respectively. We used
chi-square-based Q-test [23] and the I
2 index [24] to check the
heterogeneity among different studies. When Q-test showed the
existence of notable heterogeneity (P-value less than 0.10 and/or
I
2 index more than 50%,), we used the random-effects model
(DerSimonian and Laird method) [25]; otherwise, the fixed-effects
model (Mantel and Haenszel method) was conducted [26].
Stratification by tumor site, source of controls, ethnicity and
allele frequency in controls was conducted. All cancers were
categorized into two groups: digestive tract cancer and digestive
gland cancer. Eligible studies were classified into population-based
and hospital-based according to control source. The subjects were
classified by ethnicity into Caucasian group and Asian group. We
also classified the selected studies into C.T (C allele frequency
more than T allele frequency) group and C#T (C allele frequency
less than or equivalent to T allele frequency) group by allele
frequency in controls.
Hardy-Weinberg equilibrium (HWE) in control population was
judged by the chi-square test. P-value less than 0.05 was
Figure 1. Flow diagram of studies identification.
doi:10.1371/journal.pone.0030585.g001
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diagnosed with Egger’s linear regression method [27,28] and
funnel plot. The P-value less than 0.05 in Egger’s linear regression
indicated the presence of potential publication bias. The standard
error of logarithm for OR was plotted against its OR in funnel
plot. Begg’s funnel plot was also plotted to detect the publication
bias and influence of individual study on pooled OR. Log OR was
plotted versus standard error of Log OR for each included study in
Begg’s funnel plot [29]. And asymmetric or incomplete funnel-
shaped plots demonstrated publication bias also. In the one-way
sensitivity analysis, we excluded one single study each time, and
the new pooled results could reflect the influence of that deleted
study to the overall summary OR.
The frequency distributions of C allele in Asians and Caucasians
were compared using chi-square test. All statistical analysis was
implemented with SAS 9.2 software (SAS Institute Inc., Cary, NC,
USA), STATA 11.0 (STATA Corp, College Station, Texas) and




13 eligible studies including 12 published studies
[14,15,16,17,18,19,30,31,32,33,34,35] and 1 unpublished one
were collected in this meta-analysis according to the inclusion
criteria. Characteristics of these studies were presented in Table 1
and the genotype frequency distribution was shown in Table S1.
Among studies on head and neck squamous cell carcinoma
(HNSCC, which included oral, pharyngeal and laryngeal cancers)
[18,19], laryngeal cancer in respiratory system was not used. We
considered patients with oral cancer and pharyngeal cancer as
separate groups and pooled them into quantitative analysis
independently. Therefore, this meta-analysis employed 15 sepa-
rate case-control studies, including 4999 cases and 7606 controls,
for the polymorphism of miR-196a2.
12 studies were matched for age, sex and/or residence,
smoking, alcohol consumption [14,15,16,17,18,19,32,34,35]; 9
studies collected Asians as subjects and the other 6 investigated
Caucasians; C allele frequency of controls was the minor allele
frequency (MAF) in 7 studies and T allele frequency was MAF in
the 8 studies remained; controls in 10 studies were hospital-based
and controls of the other studies were population-based; 11 studies
described alimentary tract cancers and 4 studies focused on tumors
in digestive glands. To dilute the potential confounding bias of
HBV infection in the study of Qi et al [33], we kept the HBV
patients without HCC as controls and the HBV patients with
HCC as cases.
Genotypes in all studies were detected with genetic DNA from
blood samples using 4 genotyping methods totally. 13 out of 15
studies checked genotypes for quality control. Genotype distribu-
tion of controls in all studies was consistent with HWE, except for
Mingwu Zhang’s study on CRC.
Publication bias
We found no significant evidence of publication bias (P-
value.0.05) in any comparison model using Egger’s linear
regression method. Furthermore, the shape of funnel plot for the
allele contrast (C vs. T) showed approximately symmetric and
inverted funnel-shaped (Figure S1). Begge’s funnel plot (C vs. T)
did not reveal any remarkable asymmetry in the distribution of
scattered points (Figure 2). Among all studies included, Wang’s
study on ESCC [35] and Liu’s on PSCC [19] deviated from other
symmetrically distributed studies. When these two studies were
deleted, I
2 decreased from 63% (Ph=0.0005) to 42% (Ph=0.05).
While the summary OR for allele contrast (C vs. T) still kept
significant (OR=1.15, 95%CI=1.06–1.25), and this result was
Table 1. Characteristics of eligible studies in meta-analysis.
First author Publication Country Ethnicity Control Cancer Genotyping Matching criteria Quality HWE
Year origin source type method score
Zhan 2011 China Asian HB CRC PCR-RFLP age/sex 6.5 Y
Chen 2010 China Asian HB CRC PCR-LDR age/sex 7 Y
Zhu 2011 China Asian HB CRC TaqManSNP age/sex 7.5 Y
Zhang 2011 China Asian PB CRC PCR-RFLP age/sex 7.5 N
Wang 2010 China Asian PB ESCC SNaPshot age/sex/area 7 Y
Srivastava 2010 Indian Caucasian PB GBC PCR-RFLP age/sex 6.5 Y
Okubo 2010 Japan Asian HB GC PCR-RFLP UK 6.5 Y
Peng 2010 China Asian HB GC PCR-RFLP age/sex 6.5 Y
Li 2010 China Asian HB HCC PCR-RFLP UK 6 Y
Qi§ 2010 China Asian HB HCC PCR-LDR UK 6.5 Y
Akkiz 2011 Turkey Caucasian HB HCC PCR-RFLP age/sex/smoke 7 Y
Christensen 2010 USA Caucasian PB OSCC TaqManSNP age/sex/residence 8.5 Y
Liu 2010 USA Caucasian HB OSCC PCR-RFLP age/sex 7.5 Y
Christensen 2010 USA Caucasian PB PSCC TaqManSNP age/sex/residence 8.5 Y
Liu 2010 USA Caucasian HB PSCC PCR-RFLP age/sex 7.5 Y
CRC: colorectal cancer; ESCC: esophageal squamous cell carcinoma; GBC: gallbladder cancer; GC: gastric cancer; HCC: hepatocellular cancer; OSCC: oral cavity squamous
cancer; PSCC: pharynx squamous cancer; UK: unknown; HWE: Hardy-Weinberg equilibrium; Y: genotype frequency distribution agreed to HWE in controls; N: genotype
frequency distribution disagreed to HWE in controls; PCR-RFLP: polymerase chain reaction-restriction fragment length polymorphism; PCR-LDR: polymerase chain
reaction-ligation detection reaction; HB: hospital-based; PB: population-based; : study year; Qi§: HBV patients without HCC were controls and HBV patients with HCC
were cases in the study of Qi.
doi:10.1371/journal.pone.0030585.t001
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95%CI=1.05–1.26).
Test of heterogeneity
Between-study heterogeneities and corresponding quantitative
degrees in all comparisons and subgroups, were shown in Table
S3. After stratification, the heterogeneities decreased obviously in
the subgroups of CRC, GC, digestive gland, HCC, hospital-based
controls, and C#T group (Ph.0.10 and I
2,50% in most genetic
comparisons).
Sensitivity analysis
We deleted one single study from the overall pooled analysis each
time to check the influence of the removed data set to the overall
ORs. Two studies (Wang (ESCC) [35] and Liu (PSCC) [19])
changed the between-study heterogeneities materially in heterozy-
gote comparison andrecessive model respectively. Afterthedeletion
of anyone of the two studies mentioned, the heterogeneity vanished,
while the association still kept significant (Table S4).
Meta-analysis results
The association strength between miR-196a2 polymorphism
and the susceptibility for digestive system cancers are shown in
Table 2. Overall, there was a statistically increased risk of digestive
system cancers in every genetic comparison (CT vs. TT,
OR=1.25, 95% CI=1.07–1.45; CC vs. TT, OR=1.38, 95%
CI=1.13–1.67; CC/CT vs. TT, OR=1.29, 95% CI=1.10–1.50;
CC vs. CT/TT, OR=1.14, 95% CI=1.01–1.30; C vs. T,
OR=1.15, 95% CI=1.05–1.26).
Tumor site, source of controls, ethnicity and allele frequency in
controls were taken into consideration for subgroup analysis. The
forest plots of dominant models (CC/CT vs. TT) in different
subgroups were shown in Figure S2. Comparing with genotype
TT, heterozygote CT (OR=1.23, 95% CI=1.03–1.48), homo-
zygote CC (OR=1.32, 95% CI=1.05–1.65), combination of CT/
CC (OR=1.26, 95% CI=1.04–1.51) predominantly increased
incidences of cancers in alimentary tract. And we also found that
C allele carriers had more risks of digestive tract cancers (C vs. T,
OR=1.13, 95% CI=1.02–1.25), but no significant result was
observed in recessive model (CC vs. CT/TT, OR=1.12, 95%
CI=0.98–1.28).
Significant association between SNP rs11614913 and increased
risks of digestive gland cancers was found in three genetic models
(CT vs. TT, OR=1.30, 95% CI=1.02–1.65; CC vs. TT,
OR=1.64, 95% CI=1.24–2.17; CC/CT vs. TT, OR=1.38,
95% CI=1.10–1.74), except for recessive model (CC vs. TT,
OR=1.24, 95% CI=0.85–1.79) and allele contrast (C vs. T,
OR=1.20, 95% CI=0.96–1.51). Additionally, we demonstrated
that this locus polymorphism was significantly linked to higher
risks for CRC (CT vs. TT, OR=1.23, 95% CI=1.04–1.44; CC
vs. TT, OR=1.32, 95% CI=1.08–1.61; CC/CT vs. TT,
OR=1.25, 95% CI=1.07–1.46; C vs. T, OR=1.15, 95%
CI=1.05–1.28), but a marginal significance was found in recessive
model (CC vs. CT/TT, OR=1.16, 95% CI=0.98–1.38). We also
observed increased susceptibility of HCC in homozygote compar-
ison (OR=1.79, 95% CI=1.31–2.43), dominant model
(OR=1.41, 95% CI=1.11–1.79), recessive model (OR=1.49,
95% CI=1.16–1.91) and allele contrast (OR=1.32, 95%
CI=1.14–1.54). We just found a marginal significance in
homozygote comparison (OR=1.27, 95% CI=0.99–1.64) in
HCC study. Compared with CRC and HCC, no significant
associations were found in GC, OSCC and PSCC.
With consideration of control source, studies with hospital-
based controls showed elevated risks in four genetic comparisons
(CT vs. TT, OR=1.21, 95% CI=1.08–1.36; CC vs. TT,
OR=1.37, 95% CI=1.12–1.66; CC/CT vs. TT, OR=1.24,
95% CI=1.12–1.38; C vs. T, OR=1.16, 95% CI=1.05–1.28)
and an edge effect was obtained in recessive model (OR=1.18,
95% CI=1.00–1.40). However, studies with population-based
controls presented no significant association.
For the Asian group, every genetic comparison produced
significantly increased risks (CT vs. TT, OR=1.26, 95%
CI=1.05–1.50; CC vs. TT, OR=1.47, 95% CI=1.18–1.82;
CC/CT vs. TT, OR=1.32, 95% CI=1.10–1.57; CC vs. CT/
TT, OR=1.25, 95% CI=1.11–1.40; C vs. T, OR=1.20, 95%
Figure 2. Begg’s funnel plot of publication bias. Log OR is plotted versus standard error of Log OR for each included study. Every circle dot
represents a separate study for the indicated association by allele contrast (C over T). Wang’s study on ESCC (upper dot) and Liu’s study on PSCC
(lower dot) locate outside of pseudo 95% CI limits evidently.
doi:10.1371/journal.pone.0030585.g002
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Caucasian group.
In the subgroup of C.T, remarkably elevated cancer risks were
found in homozygote comparison (OR=1.45, 95% CI=1.01–
2.07) and dominant model (OR=1.39, 95% CI=1.02–1.90).
While we did not find significant associations among heterozygote
comparison (OR=1.36, 95% CI=1.00–1.85), recessive model
(OR=1.11, 95% CI=0.91–1.36) and allele contrast (OR=1.15,
95% CI=0.98–1.34). Meanwhile, significant association between
miR-196a2 polymorphism and increased risk of digestive system
cancer was also found in the C#T group (CT vs. TT, OR=1.18,
95% CI=1.04–1.34; CC vs. TT, OR=1.33, 95% CI=1.14–
1.55; CC/CT vs. TT, OR=1.22, 95% CI=1.08–1.37; CC vs.
CT/TT, OR=1.20, 95% CI=1.05–1.37; C vs. T, OR=1.15,
95% CI=1.07–1.24).
When we compared C allele frequency in Asians with that in
Caucasians, Zhang’s study on CRC was excluded due to its HWE
disequilibrium in controls. C allele frequency of miR-196a2
ranged from 0.419 to 0.754 across Asian and Caucasian controls.
In Asian controls, C allele frequency accounted for 45.60% which
was significantly lower than that in Caucasian controls
(59.90%,x
2=222.32, P,0.0001 ). A former study reported a
parallel observation [9].
The MOOSE Checklist for our study was shown as Table S5.
Discussion
miRNAs participate in diverse biological processes and is
regarded as a key factor in oncogenesis. SNP in miR-196a2
rs11614913 was thought to be implicated in altered expression
and function of mature miRNAs, thus contributed to modified
cancer risks. Many studies demonstrated variant in rs11614913
was significantly associated with the susceptibility of various
cancers. Hong et al. found that carriers with TC/CC genotype of
miR-196a2 had higher risks for non-small cell lung cancer
(NSCLC) comparing with TT carriers [36]. Comparing with TT
genotype, Hu et al. observed that CC or CC/CT genotypes
significantly increased breast cancer risks [37]. Similar results
were also found in glioma [38], prostatic cancer [39] and other
kinds of cancers.
Further more, SNPs in miRNAs can occasionally disturb the
gene or protein expression and result in pathogenicity [40]. Zhan
and his colleagues reported that the expression levels of miR-196a
in CC and CC/CT genotypes were higher than those in TT
genotype in CRC [15]. Li et al. also found that CC and CC/CT
genotypes increased the expression level of miR-196a in HCC
patients with HBV infection comparing with TT genotype [30].
Hu et al. found that the expression level of miR-196a in CC
genotype carriers was significantly lower than that in CT or TT
carriers with NSCLC [6]. Additionally, compared with CT/TT
genotype, CC genotype of miR-196a2 predominantly decreased
the survival time of NSCLC patients in Hu’s study [6]. Thus Hu
and his colleagues proposed the genetic variant in this locus to be a
prognostic biomarker for NSCLC.
Our study showed that the presence of C allele significantly
increased the risk of digestive system cancers with the
comparison to T allele. This finding indicates that the genetic
variant in miR-196a2 may crucially modify the susceptibility of
Table 2. Pooled ORs and 95%CIs of stratified meta-analysis.
Stratification N CT vs. TT CC vs. TT CC/CT vs. TT CC vs. CT/TT C VS. T
OR (95% CI) OR (95% CI) OR (95% CI) OR (95% CI) OR (95% CI)
Digestive cancers 15 1.25(1.07–1.45)* 1.38(1.13–1.67)* 1.29(1.10–1.50)* 1.14(1.01–1.30)* 1.15(1.05–1.26)*
Tumor site
Alimentary tract 11 1.23(1.03–1.48)* 1.32(1.05–1.65)* 1.26(1.04–1.51)* 1.12(0.98–1.28) 1.13(1.02–1.25)*
CRC 4 1.23(1.04–1.44)* 1.32(1.08–1.61)* 1.25(1.07–1.46)* 1.16(0.98–1.38) 1.15(1.05–1.28)*
GC 2 1.07(0.85–1.34) 1.24(0.94–1.65) 1.12(0.90–1.39) 1.22(0.96–1.55) 1.12(0.98–1.28)
ESCC 1 2.42(1.66–3.55)* 2.67(1.77–4.04)* 2.51(1.74–3.62)* 1.35(1.02–1.78)* 1.45(1.21–1.75)*
OSCC 2 1.00(0.47–2.13) 1.07(0.64–1.80) 1.03(0.53–1.98) 1.05(0.87–1.29) 1.04(0.91–1.19)
PSCC 2 1.35(0.79–2.32) 1.33(0.49–3.60) 1.36(0.66–2.83) 1.00(0.59–1.68) 1.09(0.72–1.63)
Digestive gland 4 1.30(1.02–1.65)* 1.64(1.24–2.17)* 1.38(1.10–1.74)* 1.24(0.85–1.79) 1.20(0.96–1.51)
HCC 3 1.27(0.99–1.64) 1.79(1.31–2.43)* 1.41(1.11–1.79)* 1.49(1.16–1.91)* 1.32(1.14–1.54)*
GBC 1 1.50(0.72–3.12) 1.04(0.51–2.11) 1.20(0.60–2.41) 0.74(0.51–1.07) 0.85(0.64–1.15)
Source of control
HB 10 1.21(1.08–1.36)* 1.37(1.12–1.66)* 1.24(1.12–1.38)* 1.18(1.00–1.40) 1.16(1.05–1.28)*
PB 5 1.37(0.84–2.22) 1.39(0.84, 2.30) 1.36(0.85–2.19) 1.09(0.94–1.27) 1.11(0.91–1.36)
Ethnicity
Asian 9 1.26(1.05–1.50)* 1.47(1.18–1.82)* 1.32(1.10–1.57)* 1.25(1.11–1.40)* 1.20(1.10–1.31)*
Caucasian 6 1.26(0.93–1.72) 1.26(0.88–1.80) 1.25(0.91–1.72) 1.02(0.83–1.27) 1.07(0.91–1.26)
Allele frequency in controls
C.T 8 1.36(1.00–1.85) 1.45(1.01–2.07)* 1.39(1.02–1.90)* 1.11(0.91–1.36) 1.15(0.98–1.34)
C#T 7 1.18(1.04–1.34)* 1.33(1.14–1.55)* 1.22(1.08–1.37)* 1.20(1.05–1.37)* 1.15(1.07–1.24)*
N: involved studies’ number; CT vs. TT: Heterozygote comparison; CC vs. TT: Homozygote comparison; CC/CT vs. TT: Dominant model; CC vs. CT/TT: Recessive model; C
VS. T: Allele contrast; Random model was chosen for data pooling when P-value,0.10 and/or I
2.50%; otherwise fixed model was used;
*: OR had statistical significance with corresponding 95%CI not including 1.
doi:10.1371/journal.pone.0030585.t002
miR-196a2 Variant Increased Digestive Cancer Risks
PLoS ONE | www.plosone.org 5 January 2012 | Volume 7 | Issue 1 | e30585digestive system cancers. Previous meta-analysis which described
cancers locating in multiple systems of organism supported our
finding [9,13].
We found that miR-196a2 polymorphism, in stratified analysis
by cancer site, was statistically related with elevated cancer risks in
the alimentary tract group and digestive gland group. Moreover,
significantly increased risks were found in CRC and HCC.
However, we did not observe any significant association between
the genetic variant and the susceptibility of GC, OSCC and
PSCC. There are some possibilities for this discrepancy among
tumor sites. Firstly, the tissue specificity leads to different cancer
susceptibilities in different tissues. Secondly, the relative small
amount of eligible studies in stratified analysis might induce
significant/insignificant association by chance due to insufficient
statistical power [41]. Two previous meta-analysis reported
insignificant association between miR-196a2 polymorphism and
HCC risks [9,13], which was inconsistent to our finding. We infer
that fewer included studies and the neglect of HBV infection in
controls might lead to insignificant results in previous meta-
analysis.
In the subgroup of ethnicity, we found significant association
between miR-196a2 polymorphism and increased risks of digestive
system cancers in Asians but not in Caucasians. A former meta-
analysis reported a parallel observation to us [9]. Inconsistency
between the two ethnicities can be explained by the possibility that
different ethnic groups live with multiple life styles and
environmental factors and thus yield diverse gene-environment
interactions [42]. And different populations carry different
genotype and/or allele frequencies of this locus polymorphism
and may lead to various degrees of cancer susceptibility [43].
Relative small sample size in Caucasians might cause the
inconspicuousness also.
The majority (70%, 7/10) of studies with hospital-based controls
recruited Asians as tested subjects and we found significantly
increased risks in this subgroup. While most (60%, 3/5) studies
with population-based controls investigated Caucasians and we
did not found any significant results in this subgroup. So the
mentioned ethnic interpretations are available to the inconsistency
in control source stratification. And the possible selection bias in
controls with different matched criteria and sample size may also
be the reasons. Chu’s meta-analysis study also reported signifi-
cantly increased cancer risks in Asians but not in Caucasians [9].
Disagreements in the stratification of allele frequency in controls
might attribute to above interpretations for ethnic effect to some
extent.
Some advantages can be highlighted in our study. On one
hand, this meta-analysis shed light on the association between
miR-196a2 polymorphism and increased risks of digestive system
cancers, CRC and HCC comprehensively and systematically. On
the other hand, the inclusion of an unpublished study on CRC
and the collection of unpublished genotype frequency of OSCC
and PSCC strengthened the power and persuasion of our
inference. Further more, all included studies had acceptable
quality (scored at least 6). Limitations of this study should be
noticed at the same time. Firstly, genetic factors, tumor biological
characteristics and their interactions with environmental factors
produce evident influences to the cancer susceptibility and
tumorigenesis. Different cancers have different risk factors and
diverse sensitivities to them. For instance, Heliobacter pylori
infections and smoking may increase the incidence of gastric
cancer. And hepatitis B, C virus infections and exposure of
aflatoxin in food are risk to liver cancer [44]. Studies included in
this meta-analysis contained various cancers, ethnic populations
and nations, and multifactor such as gender, age, lifestyle, culture
barriers, access to health care and exposure to pathogens and
carcinogens were disparate. While lacking of individual informa-
tion inhibited us from controlling the possible confounding
factors which might be caused by the inconsistencies above. We
also could not perform more precise calculation of adjusted ORs
and further analysis of potential gene-environment interactions.
Secondly, included researches did not cover all kinds of digestive
system cancers, such as pancreatic cancer. And thirdly, language
bias might derive from the screened references of English
documents only.
In summary, this meta-analysis indicated that miR-196a2
rs11614913 polymorphism may increase the susceptibility of
digestive system cancers, especially of CRC and HCC. SNP in
this locus may considerably act as a candidate of biomarker for
cancer screening, diagnosis and therapy in the future. To confirm
our findings, further well-designed studies with large sample size in
diverse ethnic populations, more types of digestive system cancers
along with tissue-specific biochemical, functional and expressional
characteristics are required.
Supporting Information
Figure S1 Funnel plot of publication bias. The standard
error of log (OR) is plotted versus OR for each study. Each square
represents a separate study for the indicated association by allele
contrast (C vs. T). The dotted line in blue indicates the estimated
OR.
(TIF)
Figure S2 Forest plots of dominant model (CC/CT vs.
TT) in different subgroups. The squares and horizontal lines
correspond to OR and 95% CI of specific study, and the area of
squares reflects study weight (inverse of the variance). The
diamond represents the pooled OR and its 95% CI.
(TIF)
Table S1 Genotype frequency distribution of studies
included.
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Table S4 ORs (95% CI) of sensitivity analysis.
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